Parabilis Medicines, Inc. (PBLS)
37.36
+0.43
(+1.16%)
USD |
NASDAQ |
Sep 22, 13:27
Parabilis Medicines Enterprise Value : 3.488B for Sept. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 21, 2026 | 3.488B |
| September 18, 2026 | 4.081B |
| September 17, 2026 | 3.976B |
| September 16, 2026 | 3.482B |
| September 15, 2026 | 3.339B |
| September 14, 2026 | 3.393B |
| September 11, 2026 | 3.482B |
| September 10, 2026 | 3.413B |
| September 09, 2026 | 3.714B |
| September 08, 2026 | 3.839B |
| September 04, 2026 | 3.919B |
| September 03, 2026 | 3.960B |
| September 02, 2026 | 3.881B |
| September 01, 2026 | 3.802B |
| August 31, 2026 | 3.745B |
| August 28, 2026 | 3.758B |
| August 27, 2026 | 3.780B |
| August 26, 2026 | 3.776B |
| August 25, 2026 | 3.773B |
| August 24, 2026 | 3.674B |
| August 21, 2026 | 3.789B |
| August 20, 2026 | 3.816B |
| August 19, 2026 | 4.031B |
| August 18, 2026 | 3.787B |
| August 17, 2026 | 3.524B |
| Date | Value |
|---|---|
| August 14, 2026 | 3.506B |
| August 13, 2026 | 3.333B |
| August 12, 2026 | 3.548B |
| August 11, 2026 | 3.432B |
| August 10, 2026 | 3.340B |
| August 07, 2026 | 3.248B |
| August 06, 2026 | 3.322B |
| August 05, 2026 | 3.238B |
| August 04, 2026 | 3.361B |
| August 03, 2026 | 3.122B |
| July 31, 2026 | 3.124B |
| July 30, 2026 | 2.914B |
| July 29, 2026 | 2.852B |
| July 28, 2026 | 2.875B |
| July 27, 2026 | 2.857B |
| July 24, 2026 | 2.791B |
| July 23, 2026 | 2.980B |
| July 22, 2026 | 2.732B |
| July 21, 2026 | 2.637B |
| July 20, 2026 | 2.300B |
| July 17, 2026 | 2.577B |
| July 16, 2026 | 2.516B |
| July 15, 2026 | 2.621B |
| July 14, 2026 | 2.774B |
| July 13, 2026 | 2.587B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 9.483B |
| Oncolytics Biotech, Inc. | 91.84M |
| Sangamo Therapeutics, Inc. | 50.28M |
| Sarepta Therapeutics, Inc. | 2.385B |
| Anixa Biosciences, Inc. | 78.42M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -52.46M |
| Revenue (Quarterly) | 0.148M |
| Total Expenses (Quarterly) | 52.61M |
| EPS Diluted (Quarterly) | -0.5421 |
| Gross Profit Margin (Quarterly) | -300.7% |
| Profit Margin (Quarterly) | -35.45K% |
| Earnings Yield | -5.12% |
| Normalized Earnings Yield | -5.037 |